Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction
Seattle, WA; Cambridge, MA; Tokyo, Japan –April 7, 2026 – Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced that the first patients have been dosed in the U.S. ASTRA Phase 3 pivotal study of AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction. AURN001 has […]
Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
Company also appoints Mark Packer, MD, as Chief Medical Officer and Jai Parekh, MD, as Chief Strategy Officer ATHERTON, Calif.–(BUSINESS WIRE)–Amaros, Inc. (www.amaros.ai), a leader in ophthalmic precision intelligence and the developer of the AI-powered AmarosEngine™ platform, today announced the launch of its Interventional Glaucoma Network (IGN), a clinician-led initiative designed to generate high-quality clinical […]
Five Reasons Market Research Should Come Before Messaging
Written by Yari Mitchell, Co-Founder and Co-CEO of LaunchLab Partners Messaging without research is just guesswork with confidence. In healthcare and medtech, it is tempting to jump straight into messaging. Teams want to define their value proposition, build a brand narrative, and start creating content that drives awareness. But without a clear understanding of the […]
Sydnexis Announces New Data from Phase 3 STAR Trial of SYD-101 Presented at 2026 AAPOS Annual Meeting
DEL MAR, Calif., March 23, 2026 – Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced new data from comprehensive subgroup analyses from the Phase 3 Study of Atropine for the Reduction of Myopia Progression (STAR) trial of SYD-101. The data were presented during an oral session at the 51st Annual Meeting of the […]
Is PR Still a ‘Thing’? Without a Doubt.
Written by Georgette “G” Pascale – Founder of G. and Friend of LaunchLab Partners Public relations is defined as “the state of the relationship between the public and a company/ organization/ other person”. Launch Lab Partners believes that trust, credibility, and visibility are the crucial factors that make PR indispensable. Most people talk about social […]
Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D.,to Chair Medical Advisory Board
Seattle, WA; Cambridge, MA; Tokyo, Japan – March 11, 2026 – Aurion Biotech, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of […]
First Patient Treated in TECLens First-in-Human Clinical Study of Revolutionary Non-Invasive Vision Correction Technology
STAMFORD, Connecticut – February 24, 2026 – TECLens, Inc., a clinical-stage ophthalmic medical device company, announced today the treatment of the initial patient for its first-in-human clinical trial evaluating the company’s groundbreaking quantitative corneal crosslinking (qCXL™) technology for non-invasive refractive vision correction. The study marks a significant milestone in the development of the first vision correction platform designed to strengthen rather than compromise corneal integrity. The clinical study will evaluate the safety and […]
DefEYE Announces Publication of Multiple Peer-Reviewed Articles Highlighting Use of Biovance 3L Ocular
Sarasota, FL – February 23, 2026 – DefEYE, Inc, a privately held ophthalmics company focused on innovative placental-based biologic solutions for ocular surface disease and surgical applications, today announced the publication of two peer-reviewed articles highlighting the use of Biovance 3L Ocular, the only tri-layer decellularized basement membrane (DBM) in ocular surgery and in ocular […]
Signs Your Brand Is Ready for PR Even If You Think It’s Not
Written by LaunchLab Partners PR Guru Amy Phillips Many healthcare brands assume public relations is something you invest in later. Often, that “later” moment is defined as after the product is perfected, after commercial launch, or after FDA approval is secured. In reality, PR is not a finish-line tactic. It is a readiness strategy. Waiting […]
Oculomics: The Eye as a Window into Whole-Body Health
Written by Yari Mitchell, Co-Founder and Co-CEO of LaunchLab Partners We’ve all heard the saying that the eye is the “window to the soul,” but emerging research suggests it may also be a powerful window into systemic health. At the Ophthalmology Innovation Source meeting in San Diego, I was introduced to a rapidly developing field […]
